.World Health Organization. Weight problems and also over weight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (2024 ).
Non-Communicable Health Condition Danger Aspect Collaboration. Worldwide trends in undersized as well as weight problems coming from 1990 to 2022: a pooled evaluation of 3663 population-representative research studies with 222 million children, teens, and adults. Lancet 403, 1027u00e2 $ “1050 (2024 ).
Articleu00c2.Google.com Scholaru00c2.Worldwide Worry Health Condition Collaborators. Global, local, and nationwide trouble of diabetes mellitus coming from 1990 to 2021, along with forecasts of prevalence to 2050: a methodical analysis for the Global Trouble of Ailment Study 2021. Lancet 402, 203u00e2 $ “234 (2023 ).
Articleu00c2.Google Scholaru00c2.Kovesdy, C. P., Furth, S. L.
& Zoccali, C & Planet Renal Day Steerage Board. Being overweight and also kidney ailment: hidden consequences of the prevalent. Renal Int.
91, 260u00e2 $ “262 (2017 ). Garofalo, C. et cetera.
An organized customer review and also meta-analysis suggests weight problems predicts onset of constant renal condition in the standard population. Kidney Int. 91, 1224u00e2 $ “1235 (2017 ).
Articleu00c2.Google.com Scholaru00c2.Jiang, Z. et cetera. Obesity and also severe renal ailment.
Are actually. J. Physiol.
Endocrinol. Metab. 324, E24u00e2 $ “E41 (2023 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Hall, J. E., carry out Carmo, J. M., da Silva, A.
A., Wang, Z. & Venue, M. E.
Excessive weight, renal dysfunction and also hypertension: mechanistic links. Nat. Rev.
Nephrol. 15, 367u00e2 $ “385 (2019 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Renal Health Condition: Improving Worldwide End Results CKD Work Group.
KDIGO 2024 Clinical Process Rule for the examination as well as administration of chronic kidney condition. Renal Int. 105, S117u00e2 $ “S314 (2024 ).
Articleu00c2.Google Scholaru00c2.Kidney Disease: Improving Global End Results Diabetic Issues Workplace Team. KDIGO 2022 Medical Process Standard for diabetic issues management in severe renal condition. Renal Int.
102, S1u00e2 $ “S127 (2022 ). Articleu00c2.Google.com Scholaru00c2.Oshima, M. et al.
Very early improvement in albuminuria with canagliflozin forecasts kidney and cardio end results: a blog post hoc analysis from the CREDENCE test. J. Am.
Soc. Nephrol. 31, 2925u00e2 $ “2936 (2020 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.de Zeeuw, D. et cetera. Proteinuria, an intended for renoprotection in patients along with style 2 diabetic person nephropathy: trainings coming from RENAAL.
Renal Int. 65, 2309u00e2 $ “2320 (2004 ). Articleu00c2.Google Scholaru00c2.Heerspink, H.
J. et al. Is actually a reduction in albuminuria connected with kidney as well as heart protection?
A post hoc study of the ALTITUDE test. Diabetic issues Obes. Metab.
18, 169u00e2 $ “177 (2016 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Michos, E. D., Bakris, G.
L., Rodbard, H. W. & Tuttle, K.
R. Glucagon-like peptide-1 receptor agonists in diabetic person renal health condition: a testimonial of their renal and heart defense. Are actually.
J. Prev. Cardiol.
14, 100502 (2023 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Muskiet, M. H.
A. et al. GLP-1 and the renal: coming from anatomy to pharmacology and also end results in diabetes.
Nat. Rev. Nephrol.
Thirteen, 605u00e2 $ “628 (2017 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Marso, S. P.
et cetera. Semaglutide as well as cardiovascular end results in patients along with type 2 diabetes. N.
Engl. J. Medication.
375, 1834u00e2 $ “1844 (2016 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Lincoff, A. M.
et cetera. Semaglutide as well as heart end results in weight problems without diabetes mellitus. N.
Engl. J. Medication.
389, 2221u00e2 $ “2232 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Perkovic, V. et cetera.
Results of semaglutide on chronic kidney ailment in individuals along with type 2 diabetes mellitus. N. Engl.
J. Medication. 391, 109u00e2 $ “121 (2024 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Colhoun, H. M. et al.
Long-term kidney outcomes of semaglutide in weight problems as well as heart disease in the SELECT trial. Nat. Medication.
30, 2058u00e2 $ “2066 (2024 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et cetera. Effects of semaglutide on albuminuria and also renal feature in folks along with over weight or being overweight along with or even without style 2 diabetes: preliminary review from the action 1, 2, and 3 tests.
Diabetes mellitus Care 46, 801u00e2 $ “810 (2023 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Shaman, A. M.
et cetera. Result of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on renal outcomes in patients along with type 2 diabetes mellitus: pooled review of SUSTAIN 6 and innovator. Blood circulation 145, 575u00e2 $ “585 (2022 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Apperloo, E. M. et cetera.
Effect of semaglutide on renal functionality throughout different amounts of baseline HbA1c, high blood pressure, body weight as well as albuminuria in SUSTAIN 6 as well as trailblazer 6. Nephrol. Dial.
Transplant. gfae150 (2024 ). Tuttle, K.
R. et cetera. Dulaglutide versus blood insulin glargine in people along with style 2 diabetic issues and also moderate-to-severe severe renal condition (AWARD-7): a multicentre, open-label, randomised trial.
Lancet Diabetes Endocrinol. 6, 605u00e2 $ “617 (2018 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H.
J. L. et al.
Change in albuminuria as a surrogate endpoint for advancement of renal ailment: a meta-analysis of procedure impacts in randomised professional trials. Lancet Diabetic Issues Endocrinol. 7, 128u00e2 $ “139 (2019 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Mann, J. F. E.
et cetera. Results of semaglutide along with and also without concomitant SGLT2 prevention make use of in participants with type 2 diabetic issues and constant renal health condition in the circulation test. Nat.
Med. https://doi.org/10.1038/s41591-024-03133-0 (2024 ). Neuen, B.
L. et al. Cardiovascular, renal and security outcomes along with GLP-1 receptor agonists alone as well as in mix along with SGLT2 inhibitors in kind 2 diabetes mellitus: an organized evaluation and also meta-analysis.
Blood circulation https://doi.org/10.1161/CIRCULATIONAHA.124.071689 (2024 ). Apperloo, E. M.
et cetera. Efficiency as well as safety and security of SGLT2 inhibitors along with as well as without glucagon-like peptide 1 receptor agonists: a SMART-C joint meta-analysis of randomised regulated trials. Lancet Diabetic Issues Endocrinol.
12, 545u00e2 $ “557 (2024 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et al. Results of tirzepatide versus the hormone insulin glargine on renal outcomes in type 2 diabetes mellitus in the SURPASS-4 test: post-hoc analysis of an open-label, randomised, phase 3 trial.
Lancet Diabetes Mellitus Endocrinol. 10, 774u00e2 $ “785 (2022 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Tuttle, K.
R. et cetera. Physical body body weight as well as eGFR throughout dulaglutide treatment in style 2 diabetes as well as moderate-to-severe constant renal health condition (AWARD-7).
Diabetes Obes. Metab. 21, 1493u00e2 $ “1497 (2019 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H. J. L.
et al. Results of tirzepatide versus blood insulin glargine on cystatin c-based kidney feature: a SURPASS-4 blog post hoc review. Diabetic issues Treatment 46, 1501u00e2 $ “1506 (2023 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Diabetic Issues Care (American Diabetic issues Association, accessed 1 September 2024) https://diabetesjournals.org/diabetes/issue/73/Supplement_1Li, K. et cetera. Impacts of bariatric surgical treatment on renal feature in obese people: an organized analysis and meta analysis.
PLoS ONE 11, e0163907 (2016 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Bilha, S. C.
et cetera. The effects of bariatric surgical treatment on renal results: an organized examine as well as meta-analysis. Obes.
Surg. 28, 3815u00e2 $ “3833 (2018 ). Articleu00c2.Google Scholaru00c2.Clerte, M.
et cetera. The measured glomerular filtering fee (mGFR) prior to and 6 months after bariatric surgery: an aviator study. Nephrol.
Ther. Thirteen, 160u00e2 $ “167 (2017 ). Articleu00c2.Google.com Scholaru00c2.Fawaz, S.
et cetera. Adiponectin decreases glomerular endothelial glycocalyx disruption and also brings back glomerular obstacle function in a mouse style of kind 2 diabetes. Diabetes 73, 964u00e2 $ “976 (2024 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Sasson, A. N. & Cherney, D.
Z. Renal hyperfiltration related to diabetes mellitus and also being overweight in individual condition. World J.
Diabetic Issues 3, 1u00e2 $ “6 (2012 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Chagnac, A. & Friedman, A.
N. Evaluating albuminuria in people along with obesity: challenges of the urinary system albumin-creatinine proportion. Renal Med.
6, 100804 (2024 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Wilding, J. P.
H. et al. Once-weekly semaglutide in grownups with over weight or being overweight.
N. Engl. J.
Medication. 384, 989u00e2 $ “1002 (2021 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Levey, A.
S. et al. An even more precise method to determine glomerular filtration amount from cream creatinine: a brand new forecast equation.
Modification of Diet in Kidney Illness Study Group. Ann. Trainee.
Med. 130, 461u00e2 $ “470 (1999 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Stevens, J.
et al. UHPLC-MS/MS approach for iohexol resolve in individual EDTA as well as lithium-heparin plasma televisions, individual urine and also in goat- and also pig EDTA plasma televisions. Bioanalysis 12, 981u00e2 $ “990 (2020 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Tuttle, K. R. et al.
Efficiency and also protection of aldosterone synthase restraint with as well as without empagliflozin for constant kidney ailment: a randomised, managed, period 2 test. Lancet 403, 379u00e2 $ “390 (2024 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.de Zeeuw, D.
et cetera. Efficiency of an unique prevention of vascular bond protein-1 in reducing albuminuria in clients with diabetic renal illness (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol.
6, 925u00e2 $ “933 (2018 ). Articleu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et al. Zibotentan in mix with dapagliflozin compared to dapagliflozin in people along with constant kidney illness (ZENITH-CKD): a multicentre, randomised, active-controlled, period 2b, professional trial.
Lancet 402, 2004u00e2 $ “2017 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et al. Impact of avenciguat on albuminuria in individuals along with CKD: two randomized placebo-controlled trials.
J. Am. Soc.
Nephrol. 25, 1227u00e2 $ “1239 (2024 ). Articleu00c2.Google Scholaru00c2.Heerspink, H.
J. L. et al.
Sparsentan in people with IgA nephropathy: a prespecified interim review from a randomised, double-blind, active-controlled clinical trial. Lancet 401, 1584u00e2 $ “1594 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.